Overall survival of patients with loss or mutation of p53 regardless of IGVH gene status compared to patients with mutated or unmutated IGVH genes with no p53 abnormality.

(A) All patients; (B) stage A patients only. The median survival of patients with mutated or unmutated IGVH genes or a p53 abnormality was 310, 119, and 47 months, respectively, for all patients, and 327, 115, and 54 months, respectively, for stage A patients.